Longeveron Reports Q3 Financial Results, Initiates Strategic Review
Biotechnology firm Longeveron reported third quarter financial results and announced the review of strategic alternatives following the failure to meet primary efficacy endpoints in its HF trial and retained a financial advisor to explore potential opportunities.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed